Grifols | GRFS - Assets


Grifols reported EUR23.29B in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
Alaunos Therapeutics USD 3.72M 1.01M Sep/2025
Arca Biopharma USD 509.25M 151.83M Sep/2025
aTyr Pharma USD 106.65M 5.12M Sep/2025
Bio Path USD 746K 1.45M Jun/2025
Brainstorm Cell Therapeutics USD 1.38M 1.19M Sep/2025
Capricor Therapeutics USD 126.44M 7.13M Sep/2025
Cara Therapeutics USD 43.75M 4.8M Jun/2025
Esperion Therapeutics USD 364.02M 16.93M Sep/2025
GlaxoSmithKline GBP 61.12B 221M Dec/2025
Grifols EUR 23.29B 3.35M Sep/2025
Immunic USD 40.7M 20.72M Sep/2025
Infinity Pharmaceuticals USD 21.23M 8.72M Jun/2023
Minerva Neurosciences USD 28.09M 2.33M Sep/2025
Nektar Therapeutics USD 301.35M 93.81M Sep/2025
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
TherapeuticsMD USD 40.13M 1.96M Jun/2024